Navigation Links
Kensey Nash and Arthrex Announce European Distribution Agreement for the Cartilage Repair Device
Date:11/9/2010

EXTON, Pa., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY), a regenerative medicine company, and Arthrex, Inc., a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons, jointly announced an agreement for the European distribution of Kensey Nash's unique Cartilage Repair Device (CRD).

Kensey Nash's CRD technology consists of a biphasic bioresorbable scaffold intended to be implanted at the site of a focal articular cartilage lesion or osteochondral defect in the knee. The product is CE Marked and indicated to support the regeneration of hyaline cartilage and subchondral bone by promoting the correct cellular morphology and structural organization during the healing process. Currently, the CRD is the subject of an FDA approved pilot clinical trial and not yet approved for sale in the US.

Pursuant to the agreement, Kensey Nash will exclusively supply the CRD to Arthrex for European marketing and distribution in accordance with the Company's CE Mark approval.  Other terms of the agreement were not disclosed.

"This partnership represents an important milestone as we continue Kensey Nash's mission as a developer of innovative regenerative medicine products," commented Joseph W. Kaufmann, President and CEO of Kensey Nash. "We look forward to building upon our excellent relationship with our strategic partner Arthrex, a highly respected global leader in the sports medicine industry," he concluded.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology.  The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials.  The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including, the cardiology, orthopaedic, sports medicine, spine, endovascular and general surgery markets.

About Arthrex, Inc.  Arthrex, headquartered in Naples, Florida, is a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons. Over 5,000 products for arthroscopic and minimally invasive orthopaedic surgical procedures have been developed by Arthrex and are currently marketed worldwide. For more information, visit www.arthrex.com.

Kensey Nash Cautionary Note for Forward-Looking Statements.  This press release contains forward-looking statements that reflect the current expectations of Kensey Nash Corporation (the "Company") about its prospects and opportunities.  The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "should," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements.  The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, Arthrex's success in selling the Company's cartilage repair product pursuant to the agreement(or otherwise), the Company's success in its research and development efforts in its cartilage repair technologies programs, the success of U.S. trials with respect to the Company's cartilage repair products and completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of its products, competition from other technologies, the Company's success in distributing its products into the marketplace, as well as tax and other risks associated with healthcare reform, economic conditions and foreign currency fluctuations. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosures under "Risk Factors" in those filings.  Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kensey Nash Announces IDE Submission for Cartilage Repair Device
2. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
4. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
5. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
6. Kensey Nash Announces $30 Million Share Buyback
7. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
8. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
9. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
10. Kensey Nash to Present at the Ninth Annual JMP Securities Research Conference
11. KENSEY NASH Receives FDA 510(k) Clearance for ECM Product, Meso BioMatrix Surgical Mesh
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, recognized ... medical devices for pressure ulcer prevention, will unveil ... Association of Critical Care Nurses, National Teaching Institute ... The Leaf Patient Monitoring System is ... the hospital environment.  The system seamlessly tracks patient ...
Breaking Medicine Technology:
(Date:6/27/2017)... and London UK (PRWEB) , ... June 27, 2017 , ... ... to a clinical study is whether they can trust the sponsor to pay them ... is vital that sponsors and CROs establish payment strategies that encourage sites to work ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... payment solution for many of the health care industry’s hospitals and provider groups, ... patient financing portal for select customers. Parasail Health is a San Francisco health-finance ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building ... SUNucate efforts, Louisiana became the sixth state to pass legislation which ensures that ... Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah and ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... A January ... been projected to reach a staggering $6.81 billion by the year 2024 according to ... at a faster rate than those made from titanium. Los Angeles area clinic Beverly ...
(Date:6/27/2017)... ... 2017 , ... The Kelahan Agency, a privately owned firm ... southern New Hampshire, is teaming up with the New Horizons for New Hampshire ... the region. , New Horizons for New Hampshire provides a wealth of services ...
Breaking Medicine News(10 mins):